OHE https://validator.w3.org/feed/docs/rss2.html Sleepio: Lessons from the Frontier of Digital Therapeutics OHE NICE Recommendation Highlights Role of Social Value Judgements The Long-term Sustainability of the NHS and Adult Social Care 5 Things You Should Do with EQ-5D Data Do child QALYs = adult QALYs? Five reasons why they might not 25 Years of the Cost Effectiveness Acceptability Curve NICE and EuroQol Research Foundation to Support New EQ-5D-5L Valuation Study The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19? How Should the World Pay for a COVID-19 Vaccine? The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’ A NICE Wind of Change? The What and So What of the NICE Methods Consultation Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments OHE at HESG Winter 2021 Does Government Funding Increase Public Sector Development of New Medicines? International Women’s Day: Why We #Choosetochallenge Efficiency Measurement in Primary Care: Time to Overcome the Challenges and Achieve Some Gains Time to Tackle the Challenges around Combination Therapies for Cancer Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions? Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far? Would Waiving COVID-19 Vaccines Patents Save Lives? Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere? ‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum Towards a New Understanding of Unmet Medical Need H.R. 3 is the Wrong Policy for the Wrong Problem The CBO Doesn’t Understand Investors CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation  Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking Does the New CBO Report Change Anything? OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare How Does Pharmaceutical Spending Drive Innovation in Europe? New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof) The cost of inaction on LDL cholesterol Rare Disease Day 2022 To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement No Smoking Day 2022: Reflecting on OHE Projections from 1994 Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet? The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed? NICE’s severity modifier: a step in the right direction, but still a long way to go Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB Let’s talk about (health) inequalities Accounting for Preference Heterogeneity in Discrete Choice Experiments Ignoring the needs of our future workforce could have disastrous consequences for the UK NHS and its patients. How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on? Open Source Modelling: From Ideas to Action Alan Maynard – Alas No More Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate